Intramuscular versus intradermal administration of anti-hepatitis B vaccine in non-cirrhotic hepatitis C patients.
Intradermal vaccination has been proposed as an alternative for the administration of anti-hepatitis B vaccine. Patients (n=66) with chronic viral hepatitis C without cirrhosis were randomised into two groups (intramuscular, n=38; and intradermal, n=28) for prospective immunisation with 20 microg recombinant vaccine, using an ultra-rapid schedule (doses at 0, 15 and 30 days). Sero-conversion (antibody level >/=10 mU/ml) in the intramuscular group was reached by 20, 40 and 72% of patients at days 15, 30 and 60 compared to 4, 8 and 36% for the intradermal group (P=0.010 at day 60). Additionally, levels rose more rapidly in the intramuscular group (P=0.004). Our results do not support the use of intradermal route of immunisation against HBV in HCV patients.
Arbizu
Eduardo Albéniz
EA
Department of Gastroenterology, Hospital Ramón y Cajal, Ctra de Colmenar km 9.1, 28034 Madrid, Spain.
Marugán
Rafael Bárcena
RB
Grijalba
Javier Yuste
JY
Serrano
Pilar López
PL
Grande
Luis Gil
LG
Del Campo Terrón
Santos
S
D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D019698:Hepatitis C, Chronic / Q000150:complications / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D014611:Vaccination
D017325:Hepatitis B Vaccines